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MK-801, a N-methyl-D-aspartate receptor antagonist, is widely used
in animal preclinical experiments to induce memory and learning
impairments and schizophrenia-like behavior. In the present study,
we compared the plasma and brain tissue concentrations ofMK-801
after intraperitoneal (i.p.) or subcutaneous (s.c.) administration at a
dose of 0.1 mg/kg in male ICR mice. Moreover, these data present
the optimization of ultra-performance liquid chromatography-
tandem mass spectrometry (UPLC-MS/MS) for the analysis of
MK-801 in biological samples. Procedures for the preparation of
brain tissue and plasma samples and instrumental analysis are
described. This article is related to a research article entitled “Effects
of the N-methyl-D-aspartate receptor antagonist, MK-801, on spatial
memory and influence of the route of administration” [1].
© 2019 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).j.bbr.2019.112067.
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Specifications Table
Subject area Pharmacology
Specific subject area Pharmacokinetics of MK-801 in mice
Type of data Figures and table of analyzed data and chromatograms
How data were
acquired
Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
Data format Raw and analyzed data
Parameters for data
collection
Mouse plasma and brain samples were taken following subcutaneous and intraperitoneal injection
of MK-801 at a dose of 0.1 mg/kg, purified on solid phase extraction (SPE), and injected into
UPLC-MS/MS to determine drug concentration over time.
Description of data
collection
Mouse brain homogenates were prepared. Blood was collected in heparin-coated tubes and
centrifuged to obtain plasma. Plasma and brain homogenate samples were pretreated by solid-
phase extraction using Strata-X reversed-phase cartridges. MK-801 concentration was determined
by ultra-performance liquid chromatography-tandem mass spectrometry.
Data source location Riga, Latvia
Data accessibility Data in the article
Related research article B. Svalbe, G. Stelfa, E. Vavers, B. Zvejniece, S. Grinberga, E. Sevostjanovs, O. Pugovics, M.Dambrova, L.
Zvejniece Effects of the N-methyl-D-aspartate receptor antagonist, MK-801, on spatial memory
and influence of the route of administration, Behav. Brain Res. 372, 2019, 112067, https://doi.org/
10.1016/j.bbr.2019.112067 [1]
Value of the data
1. The data present concentrations of MK-801 in mouse brain tissue and plasma after s.c. and i.p. administration, which is
important for experiment planning in experimental neuroscience.
2. These data will help researchers to choose the right administration route of MK-801 in the animal experiments.
3. The developed MK-801 quantification method (SPE and UPLC-MS/MS) can be used to determine MK-801 in mammalian
tissue samples.
4. The data presented in this data article show that the concentration of MK-801 in brain tissues and plasma depend on the
route of administration.
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The developed multiple reaction monitoring (MRM) method using SPE for sample pretreatment
makes it possible to determine easily the MK-801 concentration in the mouse brain homogenate,
unlike the Wegener method [2], which describes the determination of MK-801 in the brain after
microdialysis, and a more complicated sampling method.
The data depicted in Figs. 1e3 show the calibration line obtained in mouse brain homogenates and
representative MRM chromatograms of the calibration standard at the LOQ and a real mouse brain
homogenate sample after MK-801 administration.
The concentration of MK-801 was measured in blood plasma and brain tissue 15, 30, 60, 120, and
240 min after a single i.p. or s.c. administration of MK-801 at a dose of 0.1 mg/kg. The concentration of
MK-801 in the brainwas significantly higher after s.c. administration than after i.p. administration at all
time points until the 120-min time point (Table 1; Fig. 4A).
Identical effects were observed in blood plasma after MK-801 administration (Table 1; Fig. 4B).
The concentration of MK-801 in blood plasma was significantly higher following s.c. injection than
following i.p. administration until the 60-min (Fig. 4B). The maximum concentration was reached in
brain tissue and blood plasma 15min after s.c. injection and 30 min after i.p. administration of MK-801
at a dose of 0.1 mg/kg.
The maximal concentration (Cmax) of MK-801 in brain tissue and blood plasma were almost 2-fold
higher when administered via the s.c. route than the i.p. route (Table 2). The concentration of MK-801
in brain tissue was approximately 59% higher after s.c. injection than after i.p. injection, as shown by
the area under the curve (AUC, Table 2). The MK-801 AUC value for blood was over 1.5-fold higher after
s.c. injection than after i.p. injection (Table 2).
Compound name: MK-801
Correlation coefficient: r = 0.998824, r^2 = 0.997649
Calibration curve: 142.007 * x + -5.10054
Response type: External Std, Area
Curve type: Linear, Origin: Exclude, Weighting: 1/x, Axis trans: None
ng/mL














Fig. 1. Calibration line of MK-801 in mouse brain tissue homogenate from 0.1 ng/mL to 10.0 ng/mL. LOQ ¼ 0.20 ng/mL.
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2.1. Animals
All studies involving animals were conducted in accordance with ARRIVE guidelines [3,4]. Experi-
mental procedures were performed in accordance with the guidelines reported in the EU Directive
2010/63/EU and local laws and policies. All procedures were approved by the Latvian Animal Protection
Ethical Committee of Food and Veterinary Service in Riga, Latvia. Thirty male ICRmice weighing 25e30
g at the time of the pharmacokinetics experiment (Harlan Laboratories BV; Venray, Netherlands) were
housed under standard conditions (21e23 C, relative humidity of 65% ± 10%, 12-hour light-dark cycle)
with unlimited access to standard food (R70 diet, Lactamin AB, Sweden) and water.min
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Fig. 2. Representative MRM chromatogram of MK-801 in mouse brain tissue homogenate at LOQ (0.2 ng/mL).
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Fig. 3. Representative MRM chromatogram of MK-801 in mouse brain tissue homogenate e A concentration of 1.79 ng/mL was
found in the sample after 2 h of s.c. administration of MK-801 at a dose 0.1 mg/kg.
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MK-801 ((þ)-MK-801 hydrogen maleate) was dissolved in sterile saline (0.9% NaCl). MK-801 con-
centrations in the brain tissue and plasmawere determined in mice receiving single i.p. or s.c. doses of
MK-801 at 0.1mg/kg 15 and 30min, and 1, 2, and 4 hours before decapitation. Each group consisted of 3
animals for the retrieval of blood and brain samples. The brainwas divided into two hemispheres, and 6
measurements were obtained per point.Table 1
The concentration of MK-801 in blood plasma and brain tissue 15, 30, 60, and 120 min after a single i.p. or s.c. administration of
MK-801 at a dose of 0.1 mg/kg. Corresponds to Fig. 4A and B.
Group Brain tissue, ng/g Blood plasma, ng/ml
Time (min)
15 30 60 120 240 15 30 60 120 240
s.c. 96.50 71.86 34.70 14.09 3.94 4.54 4.55 2.29 0.84 0.19
93.24 76.26 33.41 15.08 6.30 5.87 3.29 1.83 0.95 0.31
73.02 73.10 40.87 13.32 5.52 4.47 3.75 2.52 0.66 0.18
106.64 80.21 42.64 16.99 6.61
98.41 71.87 38.85 21.92 7.97
74.56 77.62 39.68 17.24 6.34
Mean 90.39 75.15 38.36 16.44 6.11 4.96 3.87 2.21 0.82 0.22
SEM 5.56 1.40 1.47 1.27 0.54 0.46 0.37 0.20 0.09 0.04
i.p. 41.18 44.10 17.20 11.95 6.20 2.10 2.69 0.98 0.79 0.24
20.50 41.89 23.79 8.52 6.02 1.95 2.36 1.60 0.46 0.19
37.49 47.57 24.91 7.98 6.97 3.06 2.90 1.45 0.59 0.30
44.04 47.46 20.88 14.51 6.20
30.18 46.87 24.01 12.46 7.45
33.43 49.61 26.51 11.91 6.65
Mean 37.47 46.25 22.88 11.22 6.58 2.37 2.65 1.34 0.61 0.24
SEM 3.47 1.13 1.36 1.02 0.22 0.35 0.16 0.19 0.10 0.03
p * * * * ns * * * ns ns
The bold indicates the most important data of the table, as it shows the mean. ns e non-significant; s.c. d subcutaneous; i.p. d
intraperitoneal.
Fig. 4. Concentrations of MK-801 in brain tissue and blood plasma. Mice received a s.c. or i.p. injection of MK-801 at a dose of 0.1
mg/kg. Brain tissue (A) and blood plasma (B) samples were collected 15, 30, 60, 120, and 240 min after MK-801 administration. Each
point represents the mean (± SEM) of three mice per group. The data were analyzed for significant differences using unpaired
Student's t-test. *p < 0.05 vs. the corresponding i.p. group.
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The concentrations of MK-801 in brain tissue and plasmawere measured using UPLC-MS⁄MS. Blood
was collected in heparin-coated tubes and centrifuged at 3000 rpm at 4 C for 10 min to separate the
plasma. The brain was gently removed and homogenized in ice-cold Milli-Q water at a w/v ratio of 1:5
in 20-second bursts using a Cole Parmer 130-Watt ultrasonic processor set to 40 kHz. The obtained
homogenate was centrifuged at 16500 rpm for 10 min at 4 C. The supernatant was then decanted, and
Table 2
Pharmacokinetic parameters of MK-801 after s.c. or i.p. administration in brain tissue and blood plasma.
Administration route Brain tissue Blood plasma
Cmax (ng/g) AUC (ng min/g) Cmax (ng/ml) AUC (ng min/ml)
s.c., 0.1 mg/kg 90.4 ± 5.6 5940 ± 196* 5.0 ± 0.5 311 ± 8*
i.p., 0.1 mg/kg 46.3 ± 1.1 3733 ± 123 2.7 ± 0.2 208 ± 9
Cmaxdmaximal concentration; s.c.d subcutaneous; i.p.d intraperitoneal; AUCd area under the curve was calculated from 15
min to 240 min after drug administration. Each point represents the mean (± SEM) of three mice per group. The data were
analyzed for significant differences using unpaired Student’s t-test. *p < 0.05 vs. the corresponding i.p. group.
B. Svalbe et al. / Data in brief 27 (2019) 1046236the pellet was homogenized in the same volume of Milli-Q water as before. The obtained homogenate
was centrifuged at 16500 rpm for 10min at 4 C. The supernatants were combined and stored at80 C
until use.
Brain tissue extract (300 mL) were mixed with 700 mL of 2% formic acid aqueous solution (v/v),
vortexed und centrifuged at 13000 rpm for 10 min. 100 mL of mouse plasmawere mixed with 900 mL of
2% formic acid aqueous solution (v/v), vortexed and centrifuged at 13000 rpm for 10 min. 950 mL of the
supernatant was load onto conditioned Strata X (33mm, 30mg, 1 mL) SPE cartridge (Phenomenex),
washed 2 times with 1mL of 5% methanol aqueous solution and eluted with 900 mL of 1% formic acid
solution in acetonitrile (v/v). The eluent was evaporated using a Genevac EZ-2 at 40 C, reconstituted in
200 mL of mobile phase solution (acetonitrile/0.1% formic acid, 1:1, v/v), and subjected to UPLC-MS/MS
analysis. Calibration was performed against external calibration standard solutions.
UPLC was carried out using the Waters Acquity UPLC system equipped with the Acquity BEH C8
column (2.1  75mm, 1.7 mm). The mobile phase consisted of A (aqueous 0.1% formic acid) and B
(acetonitrile) at a flow rate of 0.25 mL/min, using a gradient elution: Initiale 50% B, 2.5 mine98% B, 4.5
mine98% B, 4.7 min 50% B, 6 mine50% B. The injection volume was 5 mL.
MS/MS analysis was performed on a Micromass Quattro MicroTM tandem mass spectrometer in
positive ion mode using multiple reaction monitoring of the transition from m/z 222.2 to 205.2 (cone
voltage 25V, collision energy 20eV). Quantitative analysis was achieved using QuanLynx 4.1 software
(Waters, Milford, USA).2.4. Chemicals
(þ)-MK-801 hydrogen maleate (5S,10R)-(þ)-5-Methyl-10,11-dihydro-5H-dibenzo [a,d]
cyclohepten-5,10-imine hydrogen maleate) was purchased from Sigma Aldrich (St Louis, Missouri,
USA). Ethanol was purchased from LAKO Ltd. (Riga, Latvia). 0.9% physiological saline was purchased
from Fresenius Kabi (Warszawa, Poland). Acetonitrile and methanol were obtained from Merck
(Darmstadt, Germany).2.5. Statistical analysis
All data were expressed as the mean ± standard error of the mean (SEM). MK-801 concentrations in
brain tissue and blood plasma were analyzed using unpaired Student's t-tests. P values less than 0.05
were significant. The statistical calculations were performed using the GraphPad Prism 3.0 software
package (GraphPad Software, Inc., La Jolla, California, USA).Acknowledgements
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